ISSN 1006-298X      CN 32-1425/R

导航

肾脏病与透析肾移植杂志 ›› 2014, Vol. 23 ›› Issue (1): 31-35.

• 论文 • 上一篇    下一篇

移植肾动脉狭窄诊断及经皮腔内血管成形术的疗效

  

  • 出版日期:2014-02-28 发布日期:2014-02-25

Clinical observations on diagnostic characteristic of transplant renal artery stenosis and curative effects of PTA

  • Online:2014-02-28 Published:2014-02-25

摘要:

摘要 目的:总结移植肾动脉狭窄患者诊断特点,分析PTA治疗效果。 方法:记录移植肾动脉狭窄患者肾功能、血压、彩超、动脉CTA在狭窄发生时的变化特点,并通过自身配对研究分析PTA治疗后临床指标变化情况以判断其疗效。结果:我中心确诊移植肾动脉狭窄患者17例,发生率为1.34%;确诊时血清肌酐(SCr)由143.1±53.7 ?mmol/L升至194.8±80.0 ?mmol/L (p<0.01),eGFR由52.3±15.6 ml/min降至36.9±10.4 ml/min(p<0.01);58.8%的患者有平均动脉压(MAP)升高;移植肾彩超提示这些患者动脉狭窄处流速均有升高,由125.9±22.9 cm/s升至331.8±132.7 cm/s(P <0.01),82.4%的患者有动脉狭窄处RI下降,由0.75±0.07降至0.61±0.17(P =0.001),而小叶间动脉流速及RI无明显变化;所有患者均由CTA确诊,进而行经皮腔内血管成形术(PTA)治疗,13例患者肾功能改善,有效率为76.5%,治疗后肾功能恢复至稳定状态的时间为7~27d,平均14.5±4.8d,另4例无改善或肾功能继续减退。PTA治疗后Scr降至153.0±43.0 ?mmol/L,eGFR升至47.9±16.1 ml/min,MAP降至93.4±7.2 mmHg,动脉狭窄处流速降至156.3±58.0 cm/s,动脉狭窄处RI升至0.74±0.08,以上指标与动脉狭窄发生前相比除MAP稍低(p=0.005)外,其余均无统计学差异(P>0.05),随访1年效果良好。结论:彩超是筛查移植肾动脉狭窄的重要手段,CTA可用于确诊,但不能忽视CTA造影剂的肾毒性;PTA治疗移植肾动脉狭窄有效率为76.5%,治疗后肾功能恢复的时间平均为14d,远期随访效果良好。 

关键词: 动脉狭窄, 肾移植, 经皮腔内血管成形术

Abstract:

ABSTRACTS OBJECTIVE: To investigate the diagnostic characteristic of transplant renal artery stenosis and the curative effects of PTA. Methodology: All the changing characteristics of renal function, blood pressure, nephritic color, artery CTA as well as DSA on transplant renal patients who got their final diagnosis of TRAS was recorded. A self-controlled study was conducted to analyze the changes of clinical factors after PTA treatment, in which the curative effects of PTA can be judged. Results: Seventeen patients were diagnosed with TRAS in our center, incidence rate of which was high to 1.34%. These people were also diagnosed with high Scr or low eGFR at various degree, whose Scr increased to(194.8±80.0)ummol/L (p<0.01)compared with the normal level of(143.1±53.7)ummol/L, and eGFR decreased to(36.9±10.4)ml/min(p<0.01)with(52.3±15.6)ml/min(p<0.01). 58.8% of the patients had higher MAP, which increased from (97.0±8.7)mmHg to (108.7±14.4)mmHg(p<0.01). Color ultrasonography also revealed that these patients had faster renal peak systolic velocity (RPSV), which increased from 125.9±22.9 cm/s to 331.8±132.7 cm/s(p<0.01). 82.4% of the patients had lower RI of the renal artery stenosis restriction, which decreased from 0.75±0.07 to 0.61±0.17(p=0.001). In contrast, there were no significant changes in the flow rate and RI of the interlobular artery. 17 patients were all revealed of artery stenosis after CTA test which followed after color ultrasonography. The degree of artery stenosis was evaluated to be 70%-90% through DSA examination. All patients were treated by PTA. Among them, 13 were found with improved renal function and the effective rate was as high as 76.5%. Vesting period was between 7-27 days (an average of 14.5±4.8). The other 4 cases were found with the same before or even damaged renal function. After being treated by PTA, their Scr was converted down to 153.0±43.0 ummol/L, eGFR up to 47.9±16.1 ml/min, MAP down to 93.4±7.2 mmHg, flow rate of artery stenosis restriction down to 156.3±58.0 cm/s, together with RI in artery stenosis restriction up to 0.74±0.08. All indexes above improved compared with those when the patients had artery stenosis, with statistical significance(p<0.05). Appositively, except for MAP, of which p=0.005, the other indexes above indicated no significant difference compared with those before artery stenosis(p>0.05). Conclusion: 1. TRAS patients are finally diagnosed with damaged renal function or abnormal arteries hemodynamics revealed by color ultrasonography. 2. PTA should be the top choice for TRAS. Vesting period on average is 14 days, with perfect clinical effects.

Key words: renal transplant,  artery stenosis,  PTA